Sanofi India Ltd
Ticker: SANOFI
Decent
66/100
☆ Add to Watchlist
Investing Reference
Price
4693.80
Market Cap
10810.11
Debt/Equity
0.0224
ROE %
44.067
PB
12.5611
Promoter %
60.396
Pledge %
0.000
1Y Rev Growth %
-7.958
5Y Rev Growth %
NP Margin %
19.410
NP Margin 5Y Avg %
Trading Reference
1M Return %
-6.983
6M Return %
-24.092
1Y Return %
-31.646
% Away 52W High
51.050
% Away 52W Low
1.520
Daily Volume
34314
Investment Verdict
Hold
Score 66/100 · Position size: 30%
Fundamentals are OK but not compelling. Maintain current position; avoid fresh adds.
Trading Verdict
Avoid
Score 24/100 · Position size: 0%
Momentum weak or trend adverse. Avoid trading at this point.
Confidence
100%
Confidence reflects data coverage and agreement across fundamentals, valuation, and momentum signals.
AI Probability Statement
Probability Statement
Sanofi India Ltd is likely to experience moderate upside potential in the medium-term, supported by recent price action near key support levels and positive volume trends. However, resistance levels may limit significant gains.
Upside Probability: 15% | Downside Probability: 10%
Probability estimates are technical-context statements, not investment advice.
More Options
S
SBFC Finance Ltd
SBFC Finance Ltd shows potential for growth but faces challenges in profitability and valuation metrics. Caution is advised.
View details
P
Prudent Corporate Advisory Services Ltd
Prudent Corporate Advisory Services Ltd shows potential for growth, but investors should be cautious of execution risks and competitive pressures.
View details
W
Westlife Foodworld Ltd
Westlife Foodworld Ltd shows potential for growth in a competitive sector, but faces challenges in profitability and valuation.
View details
W
Welspun Living Ltd
Welspun Living Ltd shows potential in a growing sector, but faces challenges in consistency and valuation.
View details
P
Powergrid Infrastructure Investment Trust
The stock has potential but faces several challenges that could impact future performance.
View details
A
Alivus Life Sciences Ltd
Alivus Life Sciences Ltd presents several risks with inconsistent growth and profitability metrics, making it a risky investment at this time.
View details
W
Waaree Renewable Technologies Ltd
Waaree Renewable Technologies Ltd shows potential in a growing sector, but faces challenges in profitability and valuation.
View details
S
Shriram Pistons & Rings Ltd
While Shriram Pistons & Rings Ltd shows potential for stability, it faces challenges in profitability and market dynamics. Caution is advised for new investments.
View details
B
Blackbuck Ltd
Blackbuck Ltd shows potential in a growing sector but faces challenges in profitability and valuation metrics.
View details
E
Eureka Forbes Ltd
Eureka Forbes Ltd shows potential in a growing sector, but faces challenges in profitability and valuation metrics.
View details
J
Jubilant Ingrevia Ltd
Jubilant Ingrevia Ltd shows potential for growth in a favorable sector, but investors should be cautious of valuation and execution risks.
View details
Z
Zee Entertainment Enterprises Ltd
Zee Entertainment Enterprises Ltd presents a risky investment due to inconsistent growth and market challenges.
View details
T
Tata Teleservices (Maharashtra) Ltd
Tata Teleservices (Maharashtra) Ltd presents a risky investment profile due to inconsistent growth, high debt, and weak market sentiment.
View details
C
Cartrade Tech Ltd
Cartrade Tech Ltd shows potential in a growing sector, but faces significant risks and inconsistencies in performance metrics.
View details
J
Jammu and Kashmir Bank Ltd
Jammu and Kashmir Bank Ltd presents a risky investment opportunity due to inconsistent growth and weak market sentiment.
View details
S
Sammaan Capital Ltd
Sammaan Capital Ltd presents several risks with limited growth prospects and governance concerns, making it a risky investment.
View details
Business Overview
Sanofi India Ltd is a leading healthcare company dedicated to improving health outcomes through innovative medicines and vaccines. With a strong presence in the Indian pharmaceutical market, it caters to a diverse range of therapeutic areas, including diabetes, cardiovascular health, and vaccines. Sanofi's commitment to research and development ensures that it remains at the forefront of medical advancements, making it a trusted choice for healthcare professionals and patients alike. Its robust distribution network and patient-centric approach further enhance its reputation as a reliable partner in health.
- Leading player in the Indian pharmaceutical sector
- Focus on innovative medicines and vaccines
- Covers diverse therapeutic areas
- Strong commitment to research and development
- Robust distribution network
- Patient-centric approach to healthcare
Investment Thesis
Sanofi India Ltd presents a compelling investment opportunity due to its strong promoter credibility, significant growth potential in digital healthcare services, and attractive valuation compared to its peers. These factors position the company well for sustained growth and shareholder value creation.
- Strong backing from the Sanofi Group enhances credibility and stability.
- Expanding digital services align with the growing trend in healthcare innovation.
- Attractive valuation metrics make it a favorable choice against industry peers.
- Robust product pipeline supports long-term revenue growth.
- Commitment to R&D ensures competitive advantage in the pharmaceutical sector.
Opportunity vs Risk
Opportunities
- Strong product pipeline ahead
- Growing healthcare demand in India
- Potential for international expansion
- Rising chronic disease prevalence
- Focus on innovation and R&D
Risks ⚠️
- Regulatory challenges in pharmaceuticals
- Intense competition in market
- Currency fluctuation impacts
- Dependence on key products
- Market volatility affecting stock price
Peer Perspective
Sanofi India Ltd trades at a premium compared to peers like Dr. Reddy's and Cipla, reflecting strong margins. A sustained focus on growth acceleration and margin stability could trigger a rerating in the stock.
Future Outlook
Sanofi India Ltd is well-positioned for growth, driven by strong product pipelines and market expansion. However, successful execution and effective cost control will be crucial to fully realize its potential in the coming years.
AI FAQs for Retail Users
- Q: What does Sanofi India Ltd do?A: Sanofi India Ltd is a pharmaceutical company that develops and manufactures medicines and vaccines.
- Q: Is Sanofi India Ltd a good investment?A: Investment decisions should be based on personal financial goals and market research.
- Q: What are the risks of investing in Sanofi India Ltd?A: Risks include market volatility, regulatory changes, and competition in the pharmaceutical sector.
- Q: How can I buy shares of Sanofi India Ltd?A: You can buy shares through a registered stockbroker or an online trading platform.
- Q: What is the dividend policy of Sanofi India Ltd?A: Sanofi India Ltd has a history of paying dividends, but future payments depend on company performance.
📊 Stock Investment Checklist (100 Points)
Sanofi India Ltd • Updated: 2025-09-17 16:30:52
-
10BusinessHighPharmaceutical sector is essential and growing, with a strong focus on innovation.
-
10GrowthHighConsistent revenue growth over the past few years, but profit growth has been moderate.
-
10ProfitabilityHighROE and ROCE are healthy, but OCF has shown some volatility.
-
10ValuationHighValuation metrics are in line with industry averages, but slightly on the higher side.
-
8BalanceHighStrong balance sheet with low debt levels and good liquidity.
-
9GovernanceHighGood promoter holding with transparent disclosures.
-
7DriversHighStrong product pipeline but faces execution risks in new markets.
-
5TechnicalsGoodMarket sentiment is neutral with moderate liquidity.
Final Score & Verdict
Score 66 / 100
• Decent
Sanofi India Ltd shows a decent investment opportunity with a solid business model and growth potential, though some risks remain.
AI Confidence Score
Instead of just “overall score,” broken into categories:
- Business Strength: 75/100
- Growth Potential: 70/100
- Profitability: 80/100
- Governance: 85/100
- Market Confidence: 78/100